Postmarketing experience with topiramate and cognition.

@article{Tatum2001PostmarketingEW,
  title={Postmarketing experience with topiramate and cognition.},
  author={William Tatum and Jacqueline A. French and Edward Faught and George L. Morris and Joyce D Liporace and Andres Miguel Kanner and Sarah L Goff and Lara Winters and Aaron Fix},
  journal={Epilepsia},
  year={2001},
  volume={42 9},
  pages={1134-40}
}
Ideal antiepileptic drugs (AEDs) are designed to stop seizures with limited central nervous system (CNS) side effects. However, CNS-related treatment-emergent adverse events (TEAEs) often occur in patients receiving AEDs. Topiramate (TPM) is an AED proven to be safe and effective as adjunctive treatment for epilepsy patients with partial seizures. Double-blind, placebo-controlled, multicenter trials demonstrated potential effects on cognition. The P.A.D.S. (post-marketing antiepileptic drug… CONTINUE READING